OliX Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

OliX Pharmaceuticals şirketinin toplam hissedar öz sermayesi ₩26.4B ve toplam borcu ₩44.0B olup, bu da borç-öz sermaye oranını 166.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₩92.5B ve ₩66.1B dir.

Anahtar bilgiler

166.8%

Borç/özkaynak oranı

₩44.02b

Borç

Faiz karşılama oranı	n/a
Nakit	₩24.44b
Eşitlik	₩26.40b
Toplam yükümlülükler	₩66.10b
Toplam varlıklar	₩92.50b

Son finansal sağlık güncellemeleri

Recent updates

OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

Nov 15

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Oct 09

Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

Aug 22

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: A226950 'nin kısa vadeli varlıkları ( ₩28.3B ) kısa vadeli yükümlülüklerini ( ₩31.3B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: A226950 'un kısa vadeli varlıkları ( ₩28.3B ) uzun vadeli yükümlülüklerini ( ₩34.8B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: A226950 'nin net borç/öz sermaye oranı ( 74.2% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: A226950 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 166.8% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: A226950 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: A226950 un, serbest nakit akışı her yıl % 27 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

OliX Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Recent updates

OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

New major risk - Financial data availability

Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

Second quarter 2024 earnings released: ₩578 loss per share (vs ₩646 loss in 2Q 2023)

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

New minor risk - Share price stability

OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors

Full year 2023 earnings released: ₩1,324 loss per share (vs ₩1,877 loss in FY 2022)

OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

Third quarter 2023 earnings released: ₩346 loss per share (vs ₩385 loss in 3Q 2022)

New minor risk - Shareholder dilution

OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia

OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment

Full year 2022 earnings released: ₩1,877 loss per share (vs ₩2,088 loss in FY 2021)

Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss

No independent directors

OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

Olix Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of Olx101a in Patients with Hypertrophic Scars

OliX Pharmaceuticals, Inc announced that it has received KRW 57 billion in funding from a group of investors

OliX Pharmaceuticals, Inc announced that it expects to receive KRW 15.000139 billion in funding from Shinhan Capital Co., Ltd. and other investors

Olix Pharmaceuticals,Inc Identifies Effective Inhibition of Target Gene Expression and Delivery of Candidate to Brain for CNS Therapeutics

No independent directors

OliX Pharmaceuticals,Inc Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate

OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Full year 2020 earnings released: ₩1,474 loss per share (vs ₩1,102 loss in FY 2019)

New 90-day low: ₩38,800

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

OliX Pharmaceuticals, Inc. Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

New 90-day high: ₩58,500

Third quarter 2020 earnings released: ₩639 loss per share

New 90-day high: ₩77,000

OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars

OliX Pharmaceuticals, Inc. Announces Expansion of Collaboration with Laboratoires Théa to Develop SiRNA Therapeutics for Ophthalmic Diseases

New 90-day high: ₩64,100

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial

New 90-day high - ₩58,600

First half earnings released

New 90-day high - ₩53,700

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin